Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment

References

• Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018;15(11):2589. doi:10.3390/ijerph15112589
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi:10.1093/humrep/deh098
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Isaoglu U, Delibas IB, Kadanali S. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res. 2011;37(8):1020–1026. doi:10.1111/j.1447-0756.2010.01478.x
   PubMed Web of Science ®Google Scholar
• Costello MF, Misso ML, Balen A, et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum Reprod Open. 2019;2019(1):hoy021. doi:10.1093/hropen/hoy021
   PubMedGoogle Scholar
• Zhu JL, Chen Z, Feng WJ, Long SL, Mo ZC. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142–148. doi:10.1016/j.cca.2019.09.010
   PubMed Web of Science ®Google Scholar
• Dapas M, Lin FTJ, Nadkarni GN, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med. 2020;17(6):e1003132. doi:10.1371/journal.pmed.1003132
   PubMed Web of Science ®Google Scholar
• Hammond GL, Wu TS, Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. Curr Opin Endocrinol Diabetes Obes. 2012;19(3):183–189. doi:10.1097/MED.0b013e328353732f
   PubMedGoogle Scholar
• Saddick SY. Identifying genes associated with the development of human polycystic ovary syndrome. Saudi J Biol Sci. 2020;27(5):1271–1279. doi:10.1016/j.sjbs.2020.01.012
   Web of Science ®Google Scholar
• Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339–352. doi:10.1111/obr.12762
   PubMed Web of Science ®Google Scholar
• Anderson AD, Solorzano CM, McCartney CR. Childhood obesity and its impact on the development of adolescent PCOS. Semin Reprod Med. 2014;32(3):202–213. doi:10.1055/s-0034-1371092
   Web of Science ®Google Scholar
• Qu X, Donnelly R. Sex Hormone-Binding Globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome. Int J Mol Sci. 2020;21(21):8191. doi:10.3390/ijms21218191
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;2:CD007506.
   Google Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi:10.1093/humrep/dey256
   PubMed Web of Science ®Google Scholar
• Hammond GL, Bocchinfuso WP. Sex hormone-binding globulin: gene organization and structure/function analyses. Horm Res. 1996;45(3–5):197–201. doi:10.1159/000184787
   Google Scholar
• Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone’s binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38(4):302–324. doi:10.1210/er.2017-00025
   PubMed Web of Science ®Google Scholar
• Karakas SE. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta. 2017;471:248–253. doi:10.1016/j.cca.2017.06.009
   PubMed Web of Science ®Google Scholar
• Ruth KS, Day FR, Tyrrell J, et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020;26(2):252–258. doi:10.1038/s41591-020-0751-5
   PubMed Web of Science ®Google Scholar
• Saez-Lopez C, Brianso-Llort L, Torres-Torronteras J, Simó R, Hammond GL, Selva DM. Resveratrol increases hepatic SHBG expression through human constitutive androstane receptor: a new contribution to the French Paradox. Sci Rep. 2017;7(1):12284. doi:10.1038/s41598-017-12509-x
   Web of Science ®Google Scholar
• Selva DM, Hammond GL. Thyroid hormones act indirectly to increase sex hormone-binding globulin production by liver via hepatocyte nuclear factor-4alpha. J Mol Endocrinol. 2009;43(1):19–27. doi:10.1677/JME-09-0025
   PubMed Web of Science ®Google Scholar
• Simó R, Saez-Lopez C, Lecube A, Hernandez C, Fort JM, Selva DM. Adiponectin upregulates SHBG production: molecular mechanisms and potential implications. Endocrinology. 2014;155(8):2820–2830. doi:10.1210/en.2014-1072
   Web of Science ®Google Scholar
• Simó R, Barbosa-Desongles A, Lecube A, Hernandez C, Selva DM. Potential role of tumor necrosis factor-α in downregulating sex hormone-binding globulin. Diabetes. 2012;61(2):372–382. doi:10.2337/db11-0727
   Web of Science ®Google Scholar
• Simó R, Barbosa-Desongles A, Hernandez C, Selva DM. IL1β down-regulation of sex hormone-binding globulin production by decreasing HNF-4α via MEK-1/2 and JNK MAPK pathways. Mol Endocrinol. 2012;26(11):1917–1927. doi:10.1210/me.2012-1152
   PubMed Web of Science ®Google Scholar
• Feng C, Jin Z, Sun L, et al. Endogenous SHBG levels correlate with that of glucose transporters in insulin resistance model cells. Mol Biol Rep. 2019;46(5):4953–4965. doi:10.1007/s11033-019-04946-w
   PubMed Web of Science ®Google Scholar
• Selva DM, Hogeveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest. 2007;117(12):3979–3987. doi:10.1172/JCI32249
   PubMed Web of Science ®Google Scholar
• Saez-Lopez C, Barbosa-Desongles A, Hernandez C, et al. Sex hormone-binding globulin reduction in metabolic disorders may play a role in NAFLD development. Endocrinology. 2017;158(3):545–559. doi:10.1210/en.2016-1668
   Web of Science ®Google Scholar
• Xie X, Liao H, Dang H, et al. Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs. Mol Endocrinol. 2009;23(4):434–443. doi:10.1210/me.2007-0531
   Google Scholar
• Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14(2):95–109. doi:10.1111/j.1467-789X.2012.01053.x
   PubMed Web of Science ®Google Scholar
• Pugeat M, Nader N, Hogeveen K, Raverot G, Déchaud H, Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol. 2010;316(1):53–59. doi:10.1016/j.mce.2009.09.020
   PubMed Web of Science ®Google Scholar
• Nokoff N, Thurston J, Hilkin A, et al. Sex differences in effects of obesity on reproductive hormones and glucose metabolism in early puberty. J Clin Endocrinol Metab. 2019;104(10):4390–4397. doi:10.1210/jc.2018-02747
   Web of Science ®Google Scholar
• Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631. doi:10.1093/humrep/dew243
   PubMed Web of Science ®Google Scholar
• Gholinezhad M, Gholsorkhtabaramiri M, Esmaeilzadeh S, Ghanbarpour A. Insulin resistance and adverse metabolic profile in overweight/obese and normal weight of young women with polycystic ovary syndrome. Caspian J Intern Med. 2018;9(3):260–267. doi:10.22088/cjim.9.3.260
   Web of Science ®Google Scholar
• Dadachanji R, Shaikh N, Mukherjee S. Genetic variants associated with hyperandrogenemia in PCOS pathophysiology. Genet Res Int. 2018;2018:7624932. doi:10.1155/2018/7624932
   PubMed Web of Science ®Google Scholar
• Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10(2):107–117. doi:10.1093/humupd/dmh010
   PubMed Web of Science ®Google Scholar
• Shorakae S, Ranasinha S, Abell S, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol (Oxf). 2018;89(5):628–633. doi:10.1111/cen.13808
   PubMed Web of Science ®Google Scholar
• Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017;37(8):1036–1047. doi:10.1080/01443615.2017.1318840
   PubMedGoogle Scholar
• Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod. 2011;85(3):431–441. doi:10.1095/biolreprod.111.092593
   PubMed Web of Science ®Google Scholar
• Simó R, Sáez-López C, Barbosa-Desongles A, Hernández C, Selva DM. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015;26(7):376–383. doi:10.1016/j.tem.2015.05.001
   PubMed Web of Science ®Google Scholar
• Handelsman DJ, Sikaris K, Ly LP. Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan. Ann Clin Biochem. 2016;53(Pt 3):377–384. doi:10.1177/0004563215610589
   Web of Science ®Google Scholar
• Shahebrahimi K, Jalilian N, Bazgir N, Rezaei M. Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab. 2016;20(6):805–809. doi:10.4103/2230-8210.192925
   PubMedGoogle Scholar
• Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223. doi:10.1152/physrev.00063.2017
   PubMed Web of Science ®Google Scholar
• Wang Y, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015;16(11):678–689. doi:10.1038/nrm4074
   PubMed Web of Science ®Google Scholar
• Tawfeek MA, Alfadhli EM, Alayoubi AM, El-Beshbishy HA, Habib FA. Sex hormone binding globulin as a valuable biochemical marker in predicting gestational diabetes mellitus. BMC Womens Health. 2017;17(1):18. doi:10.1186/s12905-017-0373-3
   PubMed Web of Science ®Google Scholar
• Le S, Xu L, Schumann M, et al. Does sex hormone-binding globulin cause insulin resistance during pubertal growth? Endocr Connect. 2019;8(5):510–517. doi:10.1530/EC-19-0044
   Web of Science ®Google Scholar
• Lin XF, Wu RR, Du J, et al. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS). Clin Exp Obstet Gynecol. 2015;42(3):315–320.
   PubMed Web of Science ®Google Scholar
• Saez-Lopez C, Villena JA, Simó R, Selva DM. Sex hormone-binding globulin overexpression protects against high-fat diet-induced obesity in transgenic male mice. J Nutr Biochem. 2020;85:108480. doi:10.1016/j.jnutbio.2020.108480
   Web of Science ®Google Scholar
• Sáez-López C, Salcedo-Allende MT, Hernandez C, Simó-Servat O, Simó R, Selva DM. Sex hormone-binding globulin expression correlates with acetyl-coenzyme A carboxylase and triglyceride content in human liver. J Clin Endocrinol Metab. 2019;104(5):1500–1507. doi:10.1210/jc.2018-00740
   Web of Science ®Google Scholar
• Selva DM, Hammond GL. Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression. Endocrinology. 2009;150(5):2183–2189. doi:10.1210/en.2008-1289
   Web of Science ®Google Scholar
• Feng C, Jin Z, Chi X, et al. SHBG expression is correlated with PI3K/AKT pathway activity in a cellular model of human insulin resistance. Gynecol Endocrinol. 2018;34(7):567–573. doi:10.1080/09513590.2017.1411474
   PubMed Web of Science ®Google Scholar
• Chang RJ. The reproductive phenotype in polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(10):688–695. doi:10.1038/ncpendmet0637
   PubMedGoogle Scholar
• Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem. 2006;43(Pt 3):217–219. doi:10.1258/000456306776865188
   Web of Science ®Google Scholar
• Huang M, Liu J, Lin X, et al. Relationship between dietary carbohydrates intake and circulating sex hormone-binding globulin levels in postmenopausal women. J Diabetes. 2018;10(6):467–477. doi:10.1111/1753-0407.12550
   PubMed Web of Science ®Google Scholar
• Ong M, Cheng J, Jin X, et al. Paeoniflorin extract reverses dexamethasone-induced testosterone over-secretion through downregulation of cytochrome P450 17A1 expression in primary murine theca cells. J Ethnopharmacol. 2019;229:97–103. doi:10.1016/j.jep.2018.09.006
   Web of Science ®Google Scholar
• Yin Y, Zhang Y, Zhang H, Jiang D, Guo G. [Clinical therapeutic effects of acupuncture combined with Chinese herbal medicine on infertility of polycystic ovary syndrome in the patients with ovulation induction with letrozole]. Zhongguo Zhen Jiu. 2018;38(1):27–32. Chinese. doi:10.13703/j.0255-2930.2018.01.006
   Google Scholar
• Longo M, Zatterale F, Naderi J, et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. 2019;20(9):2358. doi:10.3390/ijms20092358
   PubMed Web of Science ®Google Scholar
• Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: an experimental and clinical update. Endocr Connect. 2013;2(4):R30–R38. doi:10.1530/EC-13-0061
   PubMed Web of Science ®Google Scholar
• Liu CC, Huang SP, Cheng KH, et al. Lower SHBG level is associated with higher leptin and lower adiponectin levels as well as metabolic syndrome, independent of testosterone. Sci Rep. 2017;7(1):2727. doi:10.1038/s41598-017-03078-0
   Web of Science ®Google Scholar
• Simó R, Barbosa-Desongles A, Sáez-Lopez C, Lecube A, Hernandez C, Selva DM. Molecular mechanism of TNFα-induced down-regulation of SHBG expression. Mol Endocrinol. 2012;26(3):438–446. doi:10.1210/me.2011-1321
   Google Scholar
• Oróstica L, Astorga I, Plaza-Parrochia F, et al. Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome. Int J Obes (Lond). 2016;40(11):1715–1722. doi:10.1038/ijo.2016.154
   Web of Science ®Google Scholar
• Yamazaki H, Kushiyama A, Sakoda H, et al. Protective effect of sex hormone-binding globulin against metabolic syndrome: in vitro evidence showing anti-inflammatory and lipolytic effects on adipocytes and macrophages. Mediators Inflamm. 2018;2018:3062319. doi:10.1155/2018/3062319
   PubMed Web of Science ®Google Scholar
• Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocrinol. 2016;230(1):R13–R25. doi:10.1530/JOE-16-0070
   PubMed Web of Science ®Google Scholar
• Ferk P, Teran N, Gersak K. The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod. 2007;22(4):1031–1036. doi:10.1093/humrep/del457
   Web of Science ®Google Scholar
• Fan W, Li S, Chen Q, Huang Z. Association between the (TAAAA)n SHBG polymorphism and PCOS: a systematic review and meta-analysis. Gynecol Endocrinol. 2013;29(7):645–650. doi:10.3109/09513590.2013.797394
   PubMed Web of Science ®Google Scholar
• Moran LJ, Teede HJ, Noakes M, Clifton PM, Norman RJ, Wittert GA. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36(11):1004–1010. doi:10.3275/9023
   Web of Science ®Google Scholar
• Martínez-García MÁ, Gambineri A, Alpañés M, Sanchón R, Pasquali R, Escobar-Morreale HF. Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. Hum Reprod. 2012;27(12):3569–3576. doi:10.1093/humrep/des335
   PubMed Web of Science ®Google Scholar
• Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype. Eur J Endocrinol. 2008;158(6):861–865. doi:10.1530/EJE-07-0905
   Web of Science ®Google Scholar
• Cousin P, Calemard-Michel L, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab. 2004;89(2):917–924. doi:10.1210/jc.2002-021553
   Web of Science ®Google Scholar
• Hacıhanefioğlu B, Aybey B, Hakan Özön Y, Berkil H, Karşıdağ K. Association of anthropometric, androgenic and insulin-related features with polymorphisms in exon 8 of SHBG gene in women with polycystic ovary syndrome. Gynecol Endocrinol. 2013;29(4):361–364. doi:10.3109/09513590.2012.743006
   PubMed Web of Science ®Google Scholar
• Wickham EP 3rd, Ewens KG, Legro RS, Dunaif A, Nestler JE, Strauss JF 3rd. Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(4):E719–E727. doi:10.1210/jc.2010-1842
   PubMed Web of Science ®Google Scholar
• Abu-Hijleh TM, Gammoh E, Al-Busaidi AS, et al. Common variants in the Sex Hormone-Binding Globulin (SHBG) gene influence SHBG levels in women with polycystic ovary syndrome. Ann Nutr Metab. 2016;68(1):66–74. doi:10.1159/000441570
   Web of Science ®Google Scholar
• Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab. 2011;96(11):3533–3540. doi:10.1210/jc.2011-1609
   Web of Science ®Google Scholar
• Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93(11):4299–4306. doi:10.1210/jc.2008-0461
   PubMed Web of Science ®Google Scholar
• Haqq L, McFarlane J, Dieberg G, Smart N. Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis. Endocr Connect. 2014;3(1):36–46. doi:10.1530/EC-14-0010
   PubMed Web of Science ®Google Scholar
• Lim AJ, Huang Z, Chua SE, Kramer MS, Yong EL. Sleep duration, exercise, shift work and polycystic ovarian syndrome-related outcomes in a healthy population: a cross-sectional study. PLoS One. 2016;11(11):e0167048. doi:10.1371/journal.pone.0167048
   PubMed Web of Science ®Google Scholar
• Bennett WL, Aschmann HE, Puhan MA, et al. A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol. 2019;113:92–100. doi:10.1016/j.jclinepi.2019.03.014
   Web of Science ®Google Scholar
• Cirillo F, Catellani C, Lazzeroni P, et al. MiRNAs regulating insulin sensitivity are dysregulated in Polycystic Ovary Syndrome (PCOS) ovaries and are associated with markers of inflammation and insulin sensitivity. Front Endocrinol (Lausanne). 2019;10:879. doi:10.3389/fendo.2019.00879
   PubMed Web of Science ®Google Scholar
• Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab. 2012;3(1):27–47. doi:10.1177/2042018812437355
   PubMedGoogle Scholar
• Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY. Effect of metformin on microvascular endothelial function in polycystic ovary syndrome. Mayo Clin Proc. 2019;94(12):2455–2466. doi:10.1016/j.mayocp.2019.06.015
   PubMed Web of Science ®Google Scholar
• Guan Y, Wang D, Bu H, Zhao T, Wang H. The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol. 2020;2020:5150684. doi:10.1155/2020/5150684
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Romualdi D, Di Florio C, et al. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. Hum Reprod. 2012;27(10):3057–3066. doi:10.1093/humrep/des262
   PubMed Web of Science ®Google Scholar
• Tzotzas T, Karras SN, Katsiki N. Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome. Curr Vasc Pharmacol. 2017;15(3):218–229. doi:10.2174/1570161114666161221115324
   PubMed Web of Science ®Google Scholar
• Papaetis GS. Incretin-based therapies in prediabetes: current evidence and future perspectives. World J Diabetes. 2014;5(6):817–834. doi:10.4239/wjd.v5.i6.817
   Google Scholar
• Yabe D, Seino Y, Seino Y. Incretin concept revised: the origin of the insulinotropic function of glucagon-like peptide-1 - the gut, the islets or both? J Diabetes Investig. 2018;9(1):21–24. doi:10.1111/jdi.12718
   Web of Science ®Google Scholar
• Ferjan S, Jensterle M, Oblak T, et al. An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity. J Int Med Res. 2019;47(10):4691–4700. doi:10.1177/0300060519865351
   Web of Science ®Google Scholar
• Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Ther Adv Endocrinol Metab. 2021;12:2042018821989238. doi:10.1177/2042018821989238
   Web of Science ®Google Scholar
• Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820938305. doi:10.1177/2042018820938305
   Web of Science ®Google Scholar
• Heppner KM, Baquero AF, Bennett CM, et al. GLP-1R signaling directly activates arcuate nucleus kisspeptin action in brain slices but does not rescue luteinizing hormone inhibition in ovariectomized mice during negative energy balance. eNeuro. 2017;4(1):ENEURO.0198–16.2016. doi:10.1523/ENEURO.0198-16.2016
   Web of Science ®Google Scholar
• Outeiriño-Iglesias V, Romaní-Pérez M, González-Matías LC, Vigo E, Mallo F. GLP-1 increases preovulatory LH source and the number of mature follicles, as well as synchronizing the onset of puberty in female rats. Endocrinology. 2015;156(11):4226–4237. doi:10.1210/en.2014-1978
   Web of Science ®Google Scholar
• Nishiyama Y, Hasegawa T, Fujita S, et al. Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells. J Steroid Biochem Mol Biol. 2018;178:82–88. doi:10.1016/j.jsbmb.2017.11.004
   Web of Science ®Google Scholar
• Frøssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215–218. doi:10.1111/dom.13053
   PubMed Web of Science ®Google Scholar
• Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121–127. doi:10.1016/j.rbmo.2017.03.023
   PubMed Web of Science ®Google Scholar
• Xing C, Li C, He B. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. J Clin Endocrinol Metab. 2020;105(9):2950–2963. doi:10.1210/clinem/dgaa337
   PubMed Web of Science ®Google Scholar
• Wu LM, Wang YX, Zhan Y, et al. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats. Peptides. 2021;145:170624. doi:10.1016/j.peptides.2021.170624
   PubMed Web of Science ®Google Scholar
• Xing C, Lv B, Zhao H, Wang D, Li X, He B. Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. J Steroid Biochem Mol Biol. 2021;214:105992. doi:10.1016/j.jsbmb.2021.105992
   PubMed Web of Science ®Google Scholar
• Froment P, Gizard F, Staels B, Dupont J, Monget P. Un rôle pour PPARgamma dans la reproduction? [A role of PPARgamma in reproduction?]. Med Sci (Paris). 2005;21(5):507–511. doi:10.1051/medsci/2005215507
   Web of Science ®Google Scholar
• Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S. Metabolic and androgen profile in underweight women with polycystic ovary syndrome. Arch Gynecol Obstet. 2017;296(2):363–371. doi:10.1007/s00404-017-4422-9
   Web of Science ®Google Scholar
• Schoppee PD, Garmey JC, Veldhuis JD. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod. 2002;66(1):190–198. doi:10.1095/biolreprod66.1.190
   PubMed Web of Science ®Google Scholar
• Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol Obstet. 2017;296(4):661–677. doi:10.1007/s00404-017-4480-z
   PubMed Web of Science ®Google Scholar
• Jin P, Xie Y. Treatment strategies for women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(4):272–277. doi:10.1080/09513590.2017.1395841
   PubMed Web of Science ®Google Scholar
• Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005;11(3):277–291. doi:10.1093/humupd/dmi005
   PubMed Web of Science ®Google Scholar
• Amiri M, Kabir A, Nahidi F, Shekofteh M, Ramezani Tehrani F. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2018;23(1):64–77. doi:10.1080/13625187.2018.1435779
   PubMed Web of Science ®Google Scholar
• Morgante G, Cappelli V, Troìa L, De Leo V. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2020;25(3):176–181. doi:10.1080/13625187.2020.1736546
   PubMed Web of Science ®Google Scholar
• Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811–1827. doi:10.1016/j.biochi.2013.05.011
   PubMed Web of Science ®Google Scholar
• Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658. doi:10.1530/EC-17-0243
   PubMed Web of Science ®Google Scholar
• Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol. 2016;2016:1849162. doi:10.1155/2016/1849162
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198–206. doi:10.1080/09513590.2018.1540578
   PubMed Web of Science ®Google Scholar
• Zhang J, Xing C, Zhao H, He B. The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network meta-analysis. Gynecol Endocrinol. 2021;1–9. doi:10.1080/09513590.2021.2011198
   Web of Science ®Google Scholar
• Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;77(3):343–350. doi:10.1111/j.1365-2265.2012.04434.x
   PubMed Web of Science ®Google Scholar
• Krul-Poel YH, Snackey C, Louwers Y, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol. 2013;169(6):853–865. doi:10.1530/EJE-13-0617
   PubMed Web of Science ®Google Scholar
• Loughrill E, Wray D, Christides T, Zand N. Calcium to phosphorus ratio, essential elements and vitamin D content of infant foods in the UK: possible implications for bone health. Matern Child Nutr. 2017;13(3):e12368. doi:10.1111/mcn.12368
   Web of Science ®Google Scholar
• Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014;102(2):460–468.e3. doi:10.1016/j.fertnstert.2014.04.046
   PubMed Web of Science ®Google Scholar
• Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol. 2010;2010:351385. doi:10.1155/2010/351385
   PubMed Web of Science ®Google Scholar
• Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153–165. doi:10.1007/s11154-017-9424-1
   PubMed Web of Science ®Google Scholar
• Angellotti E, D’Alessio D, Dawson-Hughes B, et al. Vitamin D supplementation in patients with type 2 diabetes: the vitamin D for established type 2 diabetes (DDM2) Study. J Endocr Soc. 2018;2(4):310–321. doi:10.1210/js.2018-00015
   PubMed Web of Science ®Google Scholar
• Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67(3):460–464. doi:10.1210/jcem-67-3-460
   PubMed Web of Science ®Google Scholar
• He C, Lin Z, Robb SW, Ezeamama AE. Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta-analysis. Nutrients. 2015;7(6):4555–4577. doi:10.3390/nu7064555
   PubMed Web of Science ®Google Scholar
• Menichini D, Facchinetti F. Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review. Gynecol Endocrinol. 2020;36(1):1–5. doi:10.1080/09513590.2019.1625881
   PubMed Web of Science ®Google Scholar
• Fang F, Ni K, Cai Y, Shang J, Zhang X, Xiong C. Effect of vitamin D supplementation on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. 2017;26:53–60. doi:10.1016/j.ctcp.2016.11.008
   PubMed Web of Science ®Google Scholar
• Łagowska K, Bajerska J, Jamka M. The role of vitamin D oral supplementation in insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2018;10(11):1637. doi:10.3390/nu10111637
   PubMed Web of Science ®Google Scholar
• Guo S, Tal R, Jiang H, Yuan T, Liu Y. Vitamin D supplementation ameliorates metabolic dysfunction in patients with PCOS: a systematic review of RCTs and insight into the underlying mechanism. Int J Endocrinol. 2020;2020:7850816. doi:10.1155/2020/7850816
   PubMed Web of Science ®Google Scholar
• Azadi-Yazdi M, Nadjarzadeh A, Khosravi-Boroujeni H, Salehi-Abargouei A. The effect of vitamin D supplementation on the androgenic profile in patients with polycystic ovary syndrome: a systematic review and meta-analysis of clinical trials. Horm Metab Res. 2017;49(3):174–179. doi:10.1055/s-0043-103573
   PubMed Web of Science ®Google Scholar
• Jamilian M, Foroozanfard F, Rahmani E, Talebi M, Bahmani F, Asemi Z. Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients. 2017;9(12):1280. doi:10.3390/nu9121280
   PubMed Web of Science ®Google Scholar
• Tsai YL, Lin TL, Chang CJ, et al. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3. doi:10.1186/s12929-018-0493-6
   PubMed Web of Science ®Google Scholar
• Indira M, Venkateswarulu TC, Abraham Peele K, Nazneen Bobby M, Krupanidhi S. Bioactive molecules of probiotic bacteria and their mechanism of action: a review. 3 Biotech. 2019;9(8):306. doi:10.1007/s13205-019-1841-2
   PubMedGoogle Scholar
• Su P, Henriksson A, Mitchell H. Prebiotics enhance survival and prolong the retention period of specific probiotic inocula in an in vivo murine model. J Appl Microbiol. 2007;103(6):2392–2400. doi:10.1111/j.1365-2672.2007.03469.x
   Web of Science ®Google Scholar
• Karamali M, Eghbalpour S, Rajabi S, et al. Effects of probiotic supplementation on hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Arch Iran Med. 2018;21(1):1–7.
   PubMed Web of Science ®Google Scholar
• Nasri K, Jamilian M, Rahmani E, Bahmani F, Tajabadi-Ebrahimi M, Asemi Z. The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord. 2018;18(1):21. doi:10.1186/s12902-018-0248-0
   PubMed Web of Science ®Google Scholar
• Shamasbi SG, Ghanbari-Homayi S, Mirghafourvand M. The effect of probiotics, prebiotics, and synbiotics on hormonal and inflammatory indices in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Nutr. 2020;59(2):433–450. doi:10.1007/s00394-019-02033-1
   PubMed Web of Science ®Google Scholar